BioInsights - Cellular immuno-oncology – overcoming manufacturing and development obstacles to commercial success - spotlight

CELL & GENE THERAPY INSIGHTS

Cellular immuno-oncology – overcoming manufacturing and development obstacles to commercial success

Guest Editor:

Fritz Fiesser, Director, C&GT Engineering and Informatics at GlaxoSmithKline

June 2021

Download full spotlight

Navigating regulations: novel cell therapy platforms and their path to clinical manufacturing

N Bauer,

N Calhoun,

A Davies et al.

11 August 2021

Innovator Insight

Read more
Accelerating CAR-T process development: The power of process insight

Julia Hupfeld, Ph.D., Advanced Therapies Expert, Sartorius

29 July 2021

Webinar

Watch now
Allogeneic T-cell therapies: from R&D lab to production facility

J Dupont,

J Newell

9 June 2021

Viewpoint

Read more
Towards the rational design of a next-generation dendritic cell vaccine for cancer immunotherapy

M Bravo,

T Davies,

P Fairchild

8 June 2021

Commentary

Read more
Pursuing a fully closed cellular immunotherapy manufacturing model

E Samuel

8 June 2021

Interview

Read more
Optimizing manufacturing processes to develop novel cell and gene therapies

K Ingalls

7 June 2021

Interview

Read more
Reflecting upon the GSK–UCL collaboration on viral vector bioprocess economics for ex vivo gene therapy commercialization

S Farid

25 May 2021

Interview

Read more
Applying a closed, modular, semi-automated system to CAR T cell therapy manufacturing

Yongchang Ji, Manager of Product Applications, Cell and Gene Therapy, Thermo Fisher Scientific

Semsi Ensari, PhD, Senior Director, Kite Pharma

Nathan Moore, PhD, Associate Director, Engineering & Automation Cell Therapies, Pharmaceutical Sciences, Takeda

29 June 2021

Webinar

Watch now
A bright commercial future for off-the-shelf NK cell therapy

J Spanholtz,

T Jordansen,

V Huppert

11 May 2021

Interview

Read more
CMC obstacles in cell and gene therapy: four solutions to solve six challenges

S Viswanathan,

M Puich

10 May 2021

Innovator Insight

Read more
Navigating regulations - novel cell therapy platforms and their path to clinical manufacturing

Nina Bauer, Head of Commercial, Gene Editing and Novel Modalities, Merck KGaA

Natika Calhoun, Regulatory Consultant, Merck KGaA

Anthony Davies, Founder and CEO, Dark Horse Consulting

Matt Muldoon, Senior Director, Supplier Management, Allogene Therapeutics

27 May 2021

Webinar

Watch now